Comments

Lineage Cell Therapeutics Stock Price, Quotes and Forecasts

Q: What sector and industry does Lineage Cell Therapeutics (LCTX) operate in?

Lineage Cell Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the AMEX.

LCTXAMEX

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

$0.6523

-0.03-4.48%

At close: -

$0.6531

0.000800.12%

After Hours: 7:39 PM EDT

Lineage Cell Therapeutics (LCTX) Forecast

News Earnings Lineage Cell Therapeutics (LCTX) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Edge Rankings

Stock Score Locked: Edge Members Only

Benzinga Rankings give you vital metrics on any stock – anytime.

Unlock Rankings

Lineage Cell Therapeutics Stock Price, Quotes and Forecasts | AMEX:LCTX | Benzinga

Explore Lineage Cell Therapeutics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for LCTX.

Open	$0.68
Close	$0.65
Volume / Avg.	1.22M / 1.38M
Day Range	$0.64 - $0.69
52 Wk Range	0.37 - 1.15
Market Cap	$149.14M
P/E Ratio	-
Dividend Yield	-
Exchange	AMEX
RSI	67
Short Interest	23.42%
Days to Cover	40.09

Recent News

Lineage Cell Therapeutics, Longeveron And 2 Other Stocks Under $2 Insiders Are Buying

The Dow Jones index closed higher by around 25 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Avi Kapoor

EXCLUSIVE: Cell Therapy Player Lineage Cell Therapeutics Starts Development Activities Under Licensing Pact With Eterna Therapeutics

Lineage Cell Therapeutics Inc (NYSE: LCTX) has initiated certain development activities to generate a novel hypoimmune induced pluripotent stem cell (iPSC) line under the company’s exclusive option and license agreement with Eterna Therapeutics Inc (NASDAQ:

Vandana Singh

Why DLocal Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket

Gainers

Lisa Levin

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trends and Forecast

Dec 24

Jan

Feb

Mar

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.2

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Open	$0.68
Close	$0.65
Volume / Avg.	1.22M / 1.38M
Day Range	$0.64 - $0.69
52 Wk Range	0.37 - 1.15
Market Cap	$149.14M
P/E Ratio	-
Dividend Yield	-
Exchange	AMEX
RSI	67
Short Interest	23.42%
Days to Cover	40.09

About Lineage Cell Therapeutics Inc

Sector

Health Care

Industry

Biotechnology

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development a...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Lineage Cell Therapeutics (LCTX) stock?

You can purchase shares of Lineage Cell Therapeutics (AMEX:LCTX) through any online brokerage.

View our list of the best stock brokerages

Who are Lineage Cell Therapeutics (LCTX) competitors?

Other companies in Lineage Cell Therapeutics’s space includes: Molecular Partners (NASDAQ:MOLN), 4D Molecular Therapeutics (NASDAQ:FDMT), Voyager Therapeutics (NASDAQ:VYGR), Fate Therapeutics (NASDAQ:FATE) and Eledon Pharmaceuticals (NASDAQ:ELDN).

What is the forecast, or price target, for Lineage Cell Therapeutics (LCTX) stock?

Lineage Cell Therapeutics has a consensus price target of $4.88.

What is the current price for Lineage Cell Therapeutics (LCTX)?

The stock price for Lineage Cell Therapeutics (AMEX: LCTX) is $0.6531 last updated May 28, 2025 at 7:39 PM EDT.

Does Lineage Cell Therapeutics (LCTX) pay a dividend?

There are no upcoming dividends for Lineage Cell Therapeutics.

When is Lineage Cell Therapeutics (AMEX:LCTX) reporting earnings?

Lineage Cell Therapeutics’s Q2 earnings are confirmed for Thursday, August 7, 2025.

Is Lineage Cell Therapeutics (LCTX) going to split?

There is no upcoming split for Lineage Cell Therapeutics.

What sector and industry does Lineage Cell Therapeutics (LCTX) operate in?

Lineage Cell Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the AMEX.